Date Title Description PDF
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download

Pages

Date Title Description PDF
05 Jan 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 December 2023 and 4 January 2024 Download
29 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 December and 28 December 2023 Download
22 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 December and 21 December 2023 Download
15 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 11 December and 14 December 2023 Download
11 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 December and 8 December 2023 Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages